Contingent Value Rights - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Jul. 28, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Fair value of contingent value rights		$ 936,000		$ 936,000		$ 1,076,000
Tetraphase Pharmaceuticals Inc
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement	Jul. 28, 2020
Upfront cash for acquisition	$ 43,000,000
Business acquisition, description				As of June 30, 2022 and December 31, 2021, the holders of the CVRs are entitled to receive potential future cash payments of up to $13.5 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (ii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024
Additional aggregate payments				$ 13,500,000		$ 13,500,000
Gain (loss) recorded as other income (expense), net resulting from the change in fair value of CVRs		$ (13,000)	$ 100,000	100,000	$ (400,000)
Agreement 1 | Tetraphase Pharmaceuticals Inc
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates				4,500,000
Net sales from related parties				35,000,000
Agreement 2 | Tetraphase Pharmaceuticals Inc
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates				9,000,000
Net sales from related parties				$ 55,000,000